Drug intelligence / Profile preview

Synbiotic AKSB

Development stage: Unknown
Lead developer: Mayo Clinic
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Synbiotic AKSB is a novel synbiotic formulation developed by the Mayo Clinic in collaboration with Agri-King Corporation. It is designed as an adjuvant to enhance the immune response to influenza vaccination, particularly in elderly populations (aged 65 and older). The formulation consists of a combination of two probiotics—the bacterium Enterococcus faecium (SF68 or Ventrux ME 30) and the yeast Saccharomyces cerevisiae (Lynside Pro-Lay 1)—and a prebiotic, fructo-oligosaccharide (FOS, NutraFlora). By modulating the gut microbiota, AKSB aims to stimulate the host's immune system to improve the efficacy of seasonal vaccines. A Phase I trial has demonstrated its safety and tolerability in healthy older adults.

Other names: Agri-King Synbiotic

Beyond the preview

Go deeper on Synbiotic AKSB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synbiotic AKSB.

Explore the full profile